16 February 2010 12:32 [Source: ICIS news]
This includes an initial cash payment of €4.5bn and payments of up to €300m if certain sales milestones are achieved from 2011-2013. It also includes the assumption of certain liabilities and sale price adjustments, valued at around €360m.
"The acquisition of Solvay Pharmaceuticals is a key part of Abbott's strategy to bolster our presence in key markets and deliver sustainable, industry-leading growth," said Miles D White, Abbott’s chairman and CEO.
"In addition to taking both Abbott and Solvay products into new and expanding markets, the acquisition enhances our R&D investment, providing Abbott with the opportunity to drive future pharmaceutical growth," said White.
Abbott expects the acquisition to add approximately $2.9bn to its total reported sales for 2010, and add some $500m to its annual pharmaceutical R&D investment.
CEO of Solvay Pharmaceuticals, Werner Cautreels, will adopt a transitional role before leaving the company.
Solvay said it would now refocus its activities on accelerating its growth strategy. It planned to reinvest the proceeds in expansion in growth regions, and the development of new products with a low energy footprint and which help to reduce the cyclicality in the company’s portfolio.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|
Asian Chemical Connections